Loading...
XCSE
EMBLA
Market cap1.96bUSD
May 03, Last price  
29.50DKK
Name

Ossur hf

Chart & Performance

D1W1MN
XCSE:EMBLA chart
P/E
28.76
P/S
2.30
EPS
0.16
Div Yield, %
Shrs. gr., 5y
0.10%
Rev. gr., 5y
4.49%
Revenues
855m
+8.81%
436,274,000509,357,000483,034,000519,567,768567,818,410612,876,000686,264,000629,503,000718,669,000718,650,000785,683,000854,889,000
Net income
68m
+16.94%
40,483,00059,447,00051,243,00050,913,34757,563,63679,754,00066,040,0006,214,00063,994,00042,513,00058,389,00068,278,000
CFO
116m
+23.05%
66,154,00085,133,00065,500,00066,161,70973,779,71574,287,00095,413,00092,241,000100,530,00060,771,00094,324,000116,066,000
Dividend
Mar 13, 20200.15 DKK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers prosthetics products, including artificial limbs and related products for amputees; and lower and upper limb prosthetic components, including feet, knees, hands, fingers, liners, and other components. The company also provides bracing and supports products, such as supporting devices for spinal, knee, hip, foot, ankle, and hands that are primarily used to support joints and other body parts for therapeutic and preventative purposes; and injury solutions to enhance the healing process of bone and soft tissue injuries. It serves specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgery centers. The company sells its products through its direct sales networks and distributors. Össur hf. was founded in 1971 and is headquartered in Reykjavik, Iceland. Össur hf. is a subsidiary of William Demant Invest A/S.
IPO date
Jan 01, 2009
Employees
4,000
Domiciled in
IS
Incorporated in
IS

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT